menu
    • menu
    [{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II type-2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II type-2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II type-2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II type-2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II type-2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II type-2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II type-2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II type-2 receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II type-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II type-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II type-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II type-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II type-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Orphan Reach","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II type-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Orphan Reach","highestDevelopmentStatusID":"8","companyTruncated":"Vicore Pharma \/ Orphan Reach"},{"orgOrder":0,"company":"Vicore Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Buloxibutid","moa":"Angiotensin II type-2 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Vicore Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vicore Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vicore Pharma \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Buloxibutid

    Menu

    Buloxibutid

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vicore Pharma

                            Sweden arrow
                            AAN
                            Not Confirmed

                            Vicore Pharma

                            Sweden arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buloxibutid

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vicore Reports Positive Results from Phase 2a AIR Trial of Buloxibutid in IPF

                            Details : C21 (buloxibutid) is an angiotensin II type 2 receptor agonist, which is currently being evaluated for the treatment of patients with idiopathic pulmonary fibrosis.

                            Product Name : C21

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 20, 2024

                            Lead Product(s) : Buloxibutid

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vicore Pharma

                            Sweden arrow
                            AAN
                            Not Confirmed

                            Vicore Pharma

                            Sweden arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buloxibutid

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vicore Initiates Clinical Proof-Of-Concept Study of Endothelial Dysfunction

                            Details : C21 is an angiotensin II type 2 receptor agonist, which s being developed for the treatment endothelial dysfunction (reflecting blood vessel health) in patients with type-2-diabetes-mellitus.

                            Product Name : C21

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 05, 2023

                            Lead Product(s) : Buloxibutid

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Vicore Pharma

                            Sweden arrow
                            AAN
                            Not Confirmed

                            Vicore Pharma

                            Sweden arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buloxibutid

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vicore's AIR Study Interim Analysis Suggests that C21 Improves Lung Function in IPF Patients

                            Details : With these results, the company initiates the planning of AIR 2, a double-blind controlled phase 2 dose-finding study to confirm these results and accelerate the development of C21 in parallel to completing the AIR trial.

                            Product Name : C21

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 02, 2022

                            Lead Product(s) : Buloxibutid

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Vicore Pharma

                            Sweden arrow
                            AAN
                            Not Confirmed

                            Vicore Pharma

                            Sweden arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buloxibutid

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Orphan Reach

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vicore IPF Interim Data Selected as an Oral "Late-breaker" at the ERS Congress

                            Details : The AIR trial1 is an open label single arm phase 2 trial in treatment naïve IPF patients in which 100 mg of C21 (VP01) was administered twice daily for 24 weeks with an optional 12-week extension.

                            Product Name : C21

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 17, 2022

                            Lead Product(s) : Buloxibutid

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Orphan Reach

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Vicore Pharma

                            Sweden arrow
                            AAN
                            Not Confirmed

                            Vicore Pharma

                            Sweden arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buloxibutid

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vicore's Digital Therapeutic For IPF Patients Shows Nearly 50% Anxiety Reduction In Pilot Study

                            Details : C21 is a small molecule compound, which is in clinical development for the treatment of IPF and COVID-19. The experimental programme will assess the potential of C21 for addressing fibrosis, inflammation and vasculopathy in a variety of diseases such as ...

                            Product Name : C21

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 10, 2022

                            Lead Product(s) : Buloxibutid

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Vicore Pharma

                            Sweden arrow
                            AAN
                            Not Confirmed

                            Vicore Pharma

                            Sweden arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buloxibutid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lancet's EClinicalMedicine Publishes Phase 2 Data On C21 in COVID-19

                            Details : C21 is a first-in-class, orally available, low molecular weight, angiotensin II type 2 receptor (AT2R) agonist that activates the “protective arm” of the renin-angiotensin system (RAS) leading to resolution and regeneration following tissue damage.

                            Product Name : C21

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 25, 2021

                            Lead Product(s) : Buloxibutid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Vicore Pharma

                            Sweden arrow
                            AAN
                            Not Confirmed

                            Vicore Pharma

                            Sweden arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buloxibutid

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vicore Obtains SARS Coronavirus Patent for C21 in The USA

                            Details : C21 is first-in-class, orally available, low molecular weight, angiotensin II type 2 receptor agonist. C21 on respiratory function in COVID-19 was documented in recent phase 2 trial showing that C21 reduced need for supplemental oxygen in hospitalized pa...

                            Product Name : C21

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 22, 2021

                            Lead Product(s) : Buloxibutid

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Vicore Pharma

                            Sweden arrow
                            AAN
                            Not Confirmed

                            Vicore Pharma

                            Sweden arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buloxibutid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vicore Starts Dosing of First COVID-19 Patients in The Global Phase 3 Trial ATTRACT-3

                            Details : ATTRACT-3 is the pivotal trial in which C21, an angiotensin II type 2 receptor (AT2R) agonist, is tested for the treatment of COVID-19. C21 showed significantly reduced the extended need for supplemental oxygen therapy.

                            Product Name : C21

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 17, 2021

                            Lead Product(s) : Buloxibutid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Vicore Pharma

                            Sweden arrow
                            AAN
                            Not Confirmed

                            Vicore Pharma

                            Sweden arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buloxibutid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vicore’s C21 Reduces Long-Term Lung Injury After COVID-19 in the ATTRACT Phase 2 Extension Study

                            Details : The results showed nearly 50% reduction in lung injury in the C21 group compared with the placebo group suggest that C21 could accelerate recovery and it is currently being evaluated in a phase 3 trial in COVID-19 patients.

                            Product Name : C21

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 11, 2021

                            Lead Product(s) : Buloxibutid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Vicore Pharma

                            Sweden arrow
                            AAN
                            Not Confirmed

                            Vicore Pharma

                            Sweden arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buloxibutid

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Positive Results Show that C21 Can Become an Important Complement to COVID-19 Vaccines

                            Details : The data show restoration of lung function in COVID-19 with the company’s oral lead candidate drug C21, suggesting that C21 can become an important complement to vaccines to combat the COVID-19 pandemic.

                            Product Name : C21

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 21, 2020

                            Lead Product(s) : Buloxibutid

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth